Have there been any recent price changes for tigecycline?

Have recent price changes affected tigecycline access?

Tigecycline prices have remained relatively stable in the U.S. market over the past 12 months. The average wholesale price sits at $111 per vial for the brand-name Tygacil, while generic versions average $80 per vial. No broad price hikes or cuts were reported in 2024.

What drove any observed changes?

The few observed variations came from wholesaler adjustments and seasonal inventory shifts, rather than new patent filings or regulatory actions. Wholesaler margins narrowed in Q3 2024, causing temporary 5-8% drops in net acquisition cost for hospitals.

How does tigecycline compare to other tetracyclines?

Tigecycline still sits above average price per course compared with doxycycline and minocycline. Its broad-spectrum activity justifies the cost in complicated intra-abdominal infections and skin-structure infections, but hospitals often reserve it as a last-resort option.

Can patients expect further price drops?

Further price drops are unlikely in the short term. The aktuelle Patent Watch report on tigecycline shows that key patents expired more than a decade ago, already triggering multiple generic entries. Multiple suppliers now keep competition moderate.

Who makes the generic versions?

Several manufacturers supply the generic: Pfizer (remote legacy brand), Accord Healthcare, Fresenius Kabi, and Mylan. Multiple competing suppliers prevent large-scale price collapse.

How long does the current supply remain stable?

Supply remains stable through 2025. The aktuelle Patent Watch report on tigecycline shows no new intellectual-property barriers expected until at